Enanta Pharmaceuticals, Inc.

NasdaqGS ENTA

Enanta Pharmaceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.84

Enanta Pharmaceuticals, Inc. Debt to Equity Ratio is 0.84 for the Trailing 12 Months (TTM) ending September 30, 2024, a 704.81% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Enanta Pharmaceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.10, a 67.97% change year over year.
  • Enanta Pharmaceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.06, a 273.42% change year over year.
  • Enanta Pharmaceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.02, a -9.27% change year over year.
  • Enanta Pharmaceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 0.02, a 3,365.15% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
NasdaqGS: ENTA

Enanta Pharmaceuticals, Inc.

CEO Dr. Jay R. Luly Ph.D.
IPO Date March 21, 2013
Location United States
Headquarters 500 Arsenal Street
Employees 145
Sector Health Care
Industries
Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Similar companies

MRUS

Merus N.V.

USD 39.01

-3.56%

GLUE

Monte Rosa Therapeutics, Inc.

USD 5.56

-1.77%

RVMD

Revolution Medicines, Inc.

USD 39.83

-6.44%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

CRNX

Crinetics Pharmaceuticals, Inc.

USD 35.62

-8.62%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

IPSC

Century Therapeutics, Inc.

USD 0.94

-3.60%

CCCC

C4 Therapeutics, Inc.

USD 3.74

6.86%

STOK

Stoke Therapeutics, Inc.

USD 8.68

-2.69%

DSGN

Design Therapeutics, Inc.

USD 4.02

-2.19%

HOWL

Werewolf Therapeutics, Inc.

USD 1.35

0.00%

INBX

Inhibrx Biosciences, Inc.

USD 12.74

-6.60%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 16, 2025

Any question? Send us an email